GD
CytoMed Therapeutics Limited
GDTC · NASDAQ
$0.86 +6.87% (+$0.06)
1M -5.70%
Market Cap $13.0M
P/E Ratio -
Div. Yield -
ROE 70.74%
Piotroski F-Score Weak
2/9Valuation
44 /100
Fair P/B 1.99x
P/S 20.28x
EV/EBITDA N/A
Growth
22 /100
Declining Book val. growth 123.05%
Rev. growth 4.42%
FCF growth N/A
Profitability
0 /100
Weak Net margin 754.67%
Op. margin 672.19%
FCF margin 986.02%
Quality
1 /100
Poor ROE 70.74%
ROA 60.74%
Asset turnover 0.08x
Debt
69 /100
Low Current ratio 5.17x
Int. coverage -276.39x
Debt/Equity 0.07x
Stability
13 /100
Unstable Rev. volatility 229.77%
EPS volatility 46.34%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about GDTC
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Chee Kong Choo
Employees
42
Headquarters
Singapore
Upcoming events
13 NOV
Earnings
Upcoming earnings report